Related Experiment Video
Updated: Dec 21, 2025

Preterm EEG: A Multimodal Neurophysiological Protocol
Published on: February 18, 2012
Caffeine preserves quiet sleep in preterm neonates
Gilbert Koch1, Natalie Schönfeld1, Kerstin Jost2
1Pediatric Pharmacology and Pharmacometrics Research Center, University Children's Hospital Basel (UKBB), Basel, Switzerland.
Insights
Caffeine citrate, used for apnea of prematurity (AOP), increases wakefulness and alertness in preterm infants. This treatment affects active sleep but not quiet sleep, preserving regeneration time.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Developmental Neuroscience
Background:
- Caffeine citrate is a common treatment for apnea of prematurity (AOP) in neonatal intensive care units.
- Understanding caffeine's impact on sleep-wake cycles is crucial for optimizing care in vulnerable preterm infants.
Purpose of the Study:
- To investigate the effects of caffeine citrate on sleep-wake behavior in preterm neonates.
- To correlate caffeine concentrations with specific sleep stages and wakefulness.
Main Methods:
- Observational study of 64 preterm neonates (<32 weeks GA or <1500g birthweight).
- Sleep-wake behavior scored into active sleep, quiet sleep, and wakefulness.
- Pharmacokinetic modeling used to simulate individual neonate caffeine concentrations.
Main Results:
- In neonates with gestational age ≥28 weeks, increased caffeine levels correlated with increased wakefulness and decreased active sleep.
- Quiet sleep remained unchanged across varying caffeine concentrations in this group.
- No significant caffeine effects on sleep-wake behavior were observed in neonates with gestational age <28 weeks.
Conclusions:
- Caffeine citrate increases wakefulness and alertness in preterm neonates (GA ≥28 weeks) at the expense of active sleep.
- The drug does not appear to negatively impact quiet sleep, suggesting regeneration time may be preserved.
- Further research is needed to understand effects in extremely preterm infants (GA <28 weeks).
Abstract:
Caffeine is widely used in preterm neonates suffering from apnea of prematurity (AOP), and it has become one of the most frequently prescribed medications in neonatal intensive care units. Goal of this study is to investigate how caffeine citrate treatment affects sleep-wake behavior in preterm neonates. The observational study consists of 64 preterm neonates during their first 5 days of life with gestational age (GA) <32 weeks or very low birthweight of < 1500 g. A total of 52 patients treated with caffeine citrate and 12 patients without caffeine citrate were included. Sleep-wake behavior was scored in three stages: active sleep, quiet sleep, and wakefulness. Individual caffeine concentration of every neonate was simulated with a pharmacokinetic model. In neonates with GA ≥ 28 weeks, wakefulness increased and active sleep decreased with increasing caffeine concentrations, whereas quiet sleep remained unchanged. In neonates with GA < 28 weeks, no clear caffeine effects on sleep-wake behavior could be demonstrated. Caffeine increases fraction of wakefulness, alertness, and most probably also arousability at cost of active but not quiet sleep in preterm neonates. As such, caffeine should therefore not affect time for physical and cerebral regeneration during sleep in preterm neonates.
Related Concept Videos
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
Pharmacokinetics in Pediatric Patients: Drug Excretion

